BXT 110
Alternative Names: BXT-110Latest Information Update: 24 Nov 2025
At a glance
- Originator BrainXell Therapeutics
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Dopaminergic cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 15 Nov 2025 Pharmacodynamics data from a preclinical study in Parkinson's disease released by BrainXell Therapeutics
- 03 Nov 2025 Preclinical trials in Parkinson's disease in USA (Parenteral) prior to November 2025
- 03 Nov 2025 Pharmacodynamics data from a preclinical study in Parkinson's disease released by BrainXell Therapeutics